Reston, Va. - A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer, and follow-up scans over time correlate clearly with clinical outcomes and patient survival.
According to the Centers for Disease Control and Prevention, in 2012 (the most recent year for which numbers are available) 177,489 men in the United States were diagnosed with prostate cancer, and 27,244 men in the U.S. died from the disease.
Andrea B. Apolo, MD, chief of the Bladder Cancer Section, Center for Cancer Research, at the National Cancer Institute in Bethesda, Md., said, "To our knowledge, this is the first report of follow-up NaF scans of prostate cancer patients over a one-year period correlated with survival. The findings in this study provide support for the use of NaF-PET/CT in clinical practice in patients with advanced prostate cancer."
Sixty prostate cancer patients, including 30 with and 30 without known bone metastases by conventional imaging, underwent NaF-PET/CT at baseline, 6, and 12 months. Positive lesions were verified on follow-up scans. Changes in standardized uptake values (SUV) and lesion number were correlated with prostate-specific antigen (PSA) change, clinical impression, and overall survival. Also, greater change in SUV at 6 and 12 months correlated with greater change in PSA.
In an exploratory analysis, paired Tc-99m-MDP bone scans (TcBS) were available in 35 patients at baseline, 19 at 6 months, and 14 at 12 months. Malignant lesions on NaF-PET/CT were classified on TcBS as malignant only 65 percent of the time; 25 percent were indeterminate; and 10 percent were negative. In addition, 65 percent of paired scans showed more lesions on NaF-PET/CT than on TcBS.
The study shows that NaF-PET/CT detects more bone metastases earlier than TcBS and enhances detection of new bone disease in high-risk patients.
Apolo stated, "Our study suggests that NaF-PET/CT may be a useful imaging modality in the diagnosis, prognosis and follow-up of prostate cancer patients at high risk for bone metastasis. It provides a strong rational to further the clinical development of NaF-PET/CT as a bone imaging tool in prostate cancer and other malignancies.
Figure Caption: Improved disease on NaF-PET/CT in a 66-year-old male with mCRPC who had a PSA response to docetaxel chemotherapy. From a baseline PSA of 10.3, the PSA went down to 0.05 at 6 months and less than 0.01 at 12 months. Sequential NaF-PET/CT scans showed a significant decrease in uptake in the right pelvic skeletal lesion. Image intensities were equally adjusted.
(Credit M. Liza Lindenberg, MD, Center for Cancer Research, National Cancer Institute)
Authors of the article "Prospective Study Evaluating Na18F-Positron Emission Tomography/Computed Tomography (NaF-PET/CT) in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer" include Andrea B. Apolo, Liza Lindenberg, Joanna H. Shih, Esther Mena, Joseph W. Kim, Jong C. Park, Anna Alikhani, Yolanda Y. McKinney, Baris Turkbey, Howard L. Parnes1, Lauren V. Wood, Ravi A. Madan, James L. Gulley, William L. Dahut, Karen A. Kurdziel, and Peter L. Choyke, National Cancer Institute, National Institutes of Health, Bethesda, Md.; and Juanita Weaver, National Cancer Institute, Bethesda, Md., and Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Md.
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E.
Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.